ProBioGen Introduces Novel Productivity-Boosting Technology for Therapeutic Protein Production: “Pathway Modulator“

| Print |
Thursday, 14 June 2012 10:00 (UTC + 2)

ProBioGen_Logo_neu

Berlin, Germany, June 14, 2012 / B3C newswire / - ProBioGen announced the implementation of its new “Pathway Modulator Technology“, a permanent modification of animal cell lines for substantially improved protein yields. The Pathway Modulator Technology is royalty-free and available for new and existing cell lines either in service projects or as a license.

The Pathway Modulator Technology is highly versatile and quick: It is readily applicable to any animal cell line and, notably, even to existing producer cell lines, optimizing their productivity. The Pathway Modulator Technology works through the additional expression of an engineered enzyme in the producer cells. Upon stable transfection, the modulator enzymes’ concerted action on several cellular pathways results in substantially enhanced volumetric productivities of protein drugs. For various monoclonal antibodies and fusion proteins tested in CHO, the stable modification enhanced yields between 1.5 and 2.6-fold.

The Pathway Modulator Technology can be installed into any existing cell lines, avoiding an entire new cell line development. It lowers upstream manufacturing costs and speeds up drug development through a more rapid supply of larger quantities of bulk drug substance.

The Pathway Modulator Technology can be freely combined with other parts of ProBioGen’s Tool Box, including the GlymaxX® ADCC Enhancement Technology, the stable CHO Evaluation Platform with DG44 and K1 cell lines, and the companies’ Full Pharmaceutical CHO Expression and Media Platform.

ProBioGen is actively seeking biopharmaceutical companies with hard-to-make protein drugs or with cell lines of insufficient productivities, to challenge their current yields.

 
About ProBioGen
ProBioGen is an internationally operating technology provider and Contract Development and Manufacturing Organization (CDMO) with almost 20 years of experience in cell culture, process development, and GMP-manufacturing. ProBioGen, with its scientific excellence and strong intellectual property base, is a competent and reliable CDMO partner, offering customized solutions for even the most challenging development and manufacturing requirements. This is backed by the company’s established, fee-for-service-based CHO cell and media platform, and its innovative platform technologies, such as GlymaxX® ADCC enhancement technology, the pathway modulator technology as well as the AGE1 family of animal and human designer cell lines, as well as its comprehensive portfolio of cell-based activity assays. All services and technologies are embedded in a total quality management system to assure compliance with international ISO and GMP standards (EMA/FDA).

ProBioGen was founded 1994 and is located in Berlin, Germany.  


Contact ProBioGen
Dr Gabriele Schneider
Vice President Business Development
ProBioGen AG
Goethestrasse 54
13086 Berlin
Germany
Phone: +49 (0)30 924 006-0
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it